Artrya (AYA) Q3 2025 TU earnings summary

Executive summary

• Achieved FDA 510(k) clearance for Salix Coronary Anatomy, enabling US commercial launch and platform expansion, with three-year contracts secured with Sonic Healthcare Australia Radiology and Lumus Imaging.

• Advanced clinical validation for Salix Coronary Plaque and development of Salix Coronary Flow, both targeting future FDA submissions.

• Launched the SAPPHIRE study to validate the Plaque Dispersion Score, supporting clinical and commercial objectives in the US.

• Raised $15m in capital, increasing cash to approximately $17m post-raise in early April 2025.

Financial highlights

• Raised $15m in the quarter, with $4.65m received in Q3 and $9.38m post-quarter, boosting cash to ~$17m.

• Operating cash outflows for the quarter were $4.60m, with net cash used in operating activities of $4.60m.

• Receipts from customers totaled $6k for the quarter and $21k for the nine months.

• Related party payments during the quarter were $94,696.

• Estimated quarters of funding available at quarter end: 1.66, prior to Tranche 2 capital raise.

Outlook and guidance

• Targeting FDA clearance for Salix Coronary Plaque in Q3 CY2025 and Salix Coronary Flow by end CY2025, with 510(k) submissions planned.

• First US revenues from three partners expected in calendar year 2025.

• Expecting to reach break-even in FY 2026 and cash flow positive in FY 2027.

• Focus on accelerating commercial rollout in the US and Australia.